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ABSTRACT
Background and Objectives: Pioglitazone has been known for its anti-atherogenic effects. We compared the effects of pio-
glitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients. Subjects and Methods: 
This was a prospective, randomized single-blinded, 8-month follow-up study. Patients with significant coronary artery ste-
nosis were randomly assigned to either pioglitazone (n=19) or placebo (n=18) following zotarolimus-eluting stent (ZES) im-
plantation. Intravascular ultrasonography of the culprit vessel was performed from 20 mm distal and proximal to the stent 
at baseline. and at 8-month, and volumetric analysis was performed. Changes in inflammation markers, insulin resistance and 
lipid profile were compared. Results: Changes in atherosclerosis progression from baseline in the pioglitazone group was 
significantly lower than that of the placebo group (0.06±0.73 vs. 1.16±1.41 mm
3/mm, p=0.024, respectively), and neointima 
volume was significantly lower in the pioglitazone group compared to the placebo group (1.74±0.93 vs. 2.42±1.98 mm
3/mm, 
p=0.007, respectively). Homeostatic model assessment-index, interleukin-6, and tumor necrosis factor-α levels were signifi-
cantly lower in the pioglitazone group at 8 months. Adiponectin levels increased significantly only in the pioglitazone group. 
No significant differences in retinol binding protein-4 levels between the 2 groups were seen during the 8-month follow-up 
period. Conclusion: Compared to placebo, pioglitazone was associated with significant reduction in atherosclerosis pro-
gression and neointima formation in type 2 diabetic patients with ZES implantation. (Korean Circ J 2010;40:625-631)
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Introduction
In 2020, 300 million adults worldwide are expected to suf-
fer from diabetes and the majority will be type 2 diabetes.
1) 
The incidence of type 2 diabetes has increased rapidly, espe-
cially in Asian countries, and cardiovascular events are the most 
important causes of death in type 2 diabetic patients.
2) De-
spite great advances in coronary artery intervention, reduc-
tion in cardiovascular events and mortality in patients with 
type 2 diabetes has not been remarkable.
3)
Thiazolidinediones (TZDs), including pioglitazone and 
rosiglitazone, were introduced as insulin sensitizers. Pioglita-
zone and rosiglitazone are peroxisome proliferator-activated 
receptor (PPAR)-γ agonists, have been known for their anti-in-
flammatory effects independent of blood glucose control.
4)5) 
Because chronic low-grade inflammation results in athero-
sclerosis and cardiovascular diseases, TZDs were expected 
to have positive effects on atherosclerosis progression. Rosigli-
tazone was shown in a meta-analyses to increase the risk of 
ischemic events, including myocardial infarction.
6) On the ot-
her hand, two recent studies revealed that carotid intima me-
dia thickness regressed in patients treated with pioglitazone, 
compared to patients treated with glimepiride while both agents 626   Pioglitazone in Atherosclerosis Progression With DES
demonstrated similar HbA1c lowering effects.
7)8) The Piogli-
tazone Effect on Regression of Intravascular Sonographic Co-
ronary Obstruction Prospective Evaluation (PERISCOPE) tr-
ial showed that pioglitazone slowed the progression of athero-
sclerosis compared to glimepiride in patients with type 2 dia-
betes.
9) Pioglitazone compared with rosiglitazone appears to 
have more anti-atherogenic effects independent of the glucose 
lowering effects. The purpose of our study was to determine 
the effects of pioglitazone, when compared with placebo, on 
atherosclerotic progression and neointima formation by in-
travascular ultrasonography (IVUS) in type 2 diabetic pa-
tients following zotarolimus-eluting stent (ZES) implanta-
tion. We also investigated the changes in the levels of inflam-
matory and insulin resistance markers, such as homeostatic 
model assessment (HOMA)-index and retinol binding pro-
tein (RBP)-4, which could be affected by pioglitazone. 
Subjects and Methods
Study population
Patients were eligible for this study if they were 40 to 75 years 
of age and had type 2 diabetes. A total of 37 patients with high-
grade coronary artery lesions, defined as stenosis above 70% 
of lumen diameter, were prospectively enrolled following ZES 
implantation at the Korea University Anam Hospital cardio-
vascular centers from March 2007 to January 2008. Eligible 
patients (n=37, 15 women and 22 men) were randomly assign-
ed to receive either pioglitazone 15 mg (19 patients) or place-
bo (18 patients), in addition to standard diabetic management. 
We excluded patients with acute myocardial infarction, left 
main coronary lesion, prior history of interventional or sur-
gical treatment for coronary artery disease, heart failure defin-
ed as ejection fraction less than 45%, hepatic dysfunction, de-
fined as aspartate aminotransferase or alanine aminotrans-
ferase more than twice the upper limit, cerebrovascular dise-
ase, uncontrolled arrhythmia within 3 months, serum creati-
nine greater than 2.0 mg/dL, expected life expectancy of less 
than 1 year and previous use of PPAR-γ agonists within 3 
months before the enrollment. 
Study design
This was a prospective, randomized, single-blinded, study 
with an 8-month follow-up period, to evaluate the effects of pi-
oglitazone in reducing atherosclerosis progression in type 2 
diabetic patients. Most patients in both groups were taking 
anti-diabetic medication or insulin (85.7% vs. 78.5%) at en-
rollment. Aspirin 100 mg/day and clopidogrel 75 mg/day 
were maintained in all participants. Balloon angioplasty and 
ZES implantation were performed based on standard clini-
cal practice. This study was approved by the institute review 
board, and all participants gave written informed consent at 
study entry. Eligible patients were randomly assigned to the 
pioglitazone group (n=19) and the placebo group (n=18), and 
then underwent IVUS and blood sampling. All other medi-
cations were continued, and all patients showed good com-
pliance. After 8 months, clinical evaluation, blood sampling 
and repeat IVUS were performed to determine atheroscle-
rosis progression. The results were analyzed by the intent-to-
treat principle. Major adverse cardiovascular events (MACE), 
such as death, non-fatal myocardial infarction and the need for 
repeated target vessel or target lesion revascularization were 
noted at the 8-month follow-up. 
Angiographic analysis and intravascular ultrasound 
measurements
Coronary angiograms were obtained at baseline, immedi-
ately after stenting and after 8 months. Two identical orthogo-
nal views were obtained in each patient after intracoronary 
administration of nitrates and stored on digital CD-ROM. All 
angiographic and clinical data were analyzed in the Korea 
University Anam Hospital core laboratory. End-diastolic fra-
mes were chosen for quantitative analysis, which was perform-
ed using a computer-based TCS system, Version 2.02 (Med-
con Inc., Tel-Aviv, Israel) by an operator who was blinded to 
the patient’s information. The reference diameter, minimal lu-
minal diameter, percentage of stenosis and lesion length were 
calculated as the average value of 2 orthogonal views. The 
same views and calibration were used at follow-up angiogra-
phy. The average diameter of normal segments proximal and 
distal to the treated lesion was defined as the reference diame-
ter. Re-stenosis was defined as stenosis of greater than 50% of 
the luminal diameter. Balloon angioplasty and ZES implan-
tation were performed according to standard clinical prac-
tice. IVUS examination was performed after ZES implanta-
tion and at the 8-month follow up. The ultrasound probe was 
inserted and went along the guide wire into the distal part of 
the culprit vessel, and a motor drive was connected and with-
drew the probe at a rate of 0.5 mm/s. A follow-up IVUS study 
was done the same way on the same lesions. We examined ath-
erosclerosis progression 20 mm distal and proximal to the 
ZES during the 8-month follow-up, and neointima formation 
was observed at the stented sites at 8 months. Digitized imag-
es in 1.0 mm intervals were analyzed by an operator blinded 
to clinical information. Vessel area, defined as the internal 
volume of the external elastic membrane and the lumen area 
were measured at each cross-section. All measured vessel ar-
eas at each cross-section were added and then divided by the 
number of cross-sections in order to obtain the average ves-
sel volume per unit area. The average lumen volume per unit 
area was calculated the same way. Atheroma volume was cal-
culated by subtracting lumen volume from vessel volume, and 
atherosclerosis progression was calculated by subtracting ath-
eroma volume at the beginning of the study from the ather-
oma volume at the 8-month follow-up. Neointima volume was Sung Hye You, et al.   627
calculated by subtracting the lumen volume from the stent 
volume at the 8-month follow-up.
Laboratory analysis
Inflammatory markers, such as tumor necrosis factor (TNF)-α, 
interleukin (IL)-6 and high-sensitivity C-reactive protein (hs-
CRP) and insulin resistance markers such as basal insulin, 
HOMA index and RBP-4 were measured in both groups at 
the beginning of the study and at the 8-month follow-up visit. 
Venous blood samples were drawn from each patient after 8 
hours or overnight fasting. Blood samples were centrifuged 
to obtain plasma, which in turn was stored at -80°C. TNF-α was 
measured by a sandwich enzyme linked immuno sorbent as-
say (ELISA), with a minimum detectable level of 0.5 pg/mL 
(ALPCO Diagnostics, Salem, NH, USA). Undetectable TNF-α 
values were recorded as 0.4 pg/mL. High-sensitivity IL-6 was 
also measured by a sandwich ELISA, with a minimum detect-
able level of 0.16 pg/mL (ALPCO Diagnostics, Salem, NH, USA). 
hsCRP concentration was quantified using a latex nephelom-
eter II (Dade Behring Inc., Newark, DE, USA). Serum insulin 
was measured by microparticle enzyme immunoassay. Insulin 
resistance was assessed by the HOMA, calculated as {fasting se-
rum insulin (μU/mL)×fasting serum glucose (mmol/L)}/22.5. 
Plasma RBP-4 concentration was assessed by ELISA. Total 
cholesterol, triglyceride, high density lipoprotein-cholesterol 
and low density lipoprotein-cholesterol concentrations were 
determined by the enzymatic methods using standard bioche-
mical procedures on a B.M. Hitachi automated clinical che-
mistry analyzer (Hitachi, Tokyo, Japan).
Statistical analysis
Data are expressed as mean±SD for continuous variables, 
and data for the categorical variables are expressed as the num-
ber and the percentage of patients. Fisher’s exact test or the chi-
square test was used for categoric variables. The results be-
tween groups were compared by the Mann-Whitney U test, 
Table 1. Baseline patients characteristics
Pioglitazone (n=19) Placebo (n=18) p
Age (year) 059.4±6.4 00.62.0±7.4 0.265
Sex, n (%)
Male  11 (57.9) 11 (61.1) 1.000
Body-mass index 24.92±2.04 26.05±3.21 0.482
Hypertension, n (%) 11 (57.9) 11 (61.1) 1.000
Current smoker, n (%) 05 (26.3) 05 (27.8) 1.000
Family history of premature CHD, n (%) 0 (0)0. 0 (0)0. NA
CVA history, n (%) 0 (0)0. 0 (0)0. NA
Unstable angina, n (%)  07 (36.8) 03 (16.7) 0.236
Medication at discharge, n (%)
Aspirin use 19 (100). 18 (100). 1.000
Clopidogrel use 19 (100). 18 (100). 1.000
Herben use 08 (42.1) 07 (38.9) 1.000
Nitrate use 08 (42.1) 08 (44.4) 1.000
Sigmart use 05 (26.3) 1 (5.6) 0.165
ACEI or ARB use 13 (68.4) 12 (66.7) 1.000
Beta blocker use 03 (15.8) 11 (61.1) 0.007*
Calcium channel blocker use 03 (15.8) 02 (11.1) 1.000
Diuretics use 0 (0)0. 04 (22.2) 0.098
Statin use 15 (78.9) 16 (88.9) 0.648


























*p<0.05: statistically significant. CHD: coronary heart disease, CVA: cardiovascular accident, ACEI: angiotension converting enzyme inhibi-
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and comparisons between results pre and post treatment were 
analyzed by the Wilcoxon matched-pairs single-rank test. 
Simple correlation analysis was performed by the Spearman’s 
rank order correlation. A p less than 0.05 was considered sta-
tistically significant. Statistical Package for the Social Scienc-
es (SPSS) software (version 10.0) was used for analyses (SPSS 
Inc., Chicago, IL, USA).
Results
Patient population and clinical findings
Risk factors such as hypertension and smoking were the 
same between the two groups (Table 1). Target vessels were 
similar between the two groups. Baseline reference diameter, 
minimal lumen diameter and stenosis diameter were similar 
between the two groups (Table 1). Most patients were taking 
an oral diabetic medication before enrollment (89.5% vs. 77.8%) 
(Table 1). The use of angiotensin converting enzyme inhibi-
tors or angiotensin receptor blockers were similar between 
the two groups, and atorvastatin 10 mg was maintained in 
all participants unless contraindicated. 
There were no significant differences in baseline angiogra-
phic characteristics between the two groups, and the 8-month 
follow-up minimal lumen diameters were higher in the piogl-
Table 2. Results of angiographic characteristics
Pioglitazone (n=19) Placebo (n=18) p
Target coronary artery, n (%)













Minimal lumen diameter (mm)












In segment 3.12±0.34 3.09±0.40 0.535
In stent 3.04±0.27 2.99±0.36 0.428
Minimal lumen diameter (mm)
In segment 2.95±0.35 2.88±0.39 0.525
In stent 2.97±0.30 2.92±0.37 0.712
Percentage of stenosis (%)
In segment 5.45±2.88 6.80±3.01 0.272
In stent 2.30±2.24 2.34±2.31 0.880
Acute gain (mm)
In segment 2.34±0.61 2.42±0.59 0.613
In stent 2.36±0.68 2.46±0.62 0.687
8-month follow-up
Reference diameter (mm)
In segment 3.14±0.42 3.11±0.47 0.632
In stent 3.06±0.37 3.02±0.39 0.563
Minimal lumen diameter (mm)
In segment 2.65±0.81 2.31±0.91 0.071
In stent 2.51±0.74 2.13±0.89 0.105
Percentage of stenosis (%)
In segment 15.6±21.3 25.7±24.7 0.088
In stent 18.0±20.3 29.5±29.2 0.132
Late lumen loss (mm)
In segment 0.30±0.52 0.57±0.83 0.112
In stent 0.46±0.69 0.79±0.80 0.144Sung Hye You, et al.   629
itazone group, albeit without statistically significant differ-
ence (Table 2).
Changes in atherosclerosis progression 
Baseline vessel volume, lumen volume and atheroma vol-
ume were similar between the two groups in atherosclerosis 
progression 20 mm proximal and distal to the stent (p=not sig-
nificant). Mean change in atheroma volume was significant-
ly lower in the pioglitazone group, compared to the placebo 
group at 8-month follow-up (0.06±0.73 vs. 1.16±1.41 mm
3/
mm, p=0.024, respectively) (Table 3). Atherosclerosis progres-
sion at 8 months was significantly greater compared to that 
of baseline in the placebo group (7.77±4.47 vs. 6.61±4.66 
mm
3/mm, p=0.016, respectively). On the other hand, there 
was no significant atherosclerosis progression at 8 months 
compared to baseline in the pioglitazone Group (5.24±2.89 vs. 
5.18±2.69 mm
3/mm, p=0.826). Changes in atheroma volume 
20 mm proximal and distal to the stent were significantly lo-
wer in the pioglitazone group (Fig. 1A). Changes in athero-
ma volume are further divided into segments 5 mm immedi-
ately proximal and distal to the stent, and 5 to 20 mm proximal 
and distal to the stent. Changes in atheroma volume 5 mm 
immediately proximal and distal to the stent were higher than 
that of atheroma volume 5 to 20 mm proximal and distal to 
the stent (Fig. 1B).
In-stent neointima volume changes during follow-up
The pioglitazone group showed significantly lower neointi-
ma volume compared to the placebo group (1.74±0.93 vs. 
2.42±1.98, p=0.007, respectively) (Fig. 1A). Two cases of in-
stent re-stenosis were noted in the placebo group, and all of 
them belong to the diffuse proliferative type. One case of in-
stent re-stenosis in the pioglitazone group belong to the fo-
cal type. No correlation was found between change in ather-
oma volume and neointima volume in all 37 patients (r=0.126, 
p=0.521).
Changes in the levels of inflammatory and insulin 
resistance markers
Baseline IL-6 and TNF-α concentrations were similar at 
baseline between the two groups. However, IL-6 and TNF-α 
concentrations at 8 months were significantly lower in the pi-
oglitazone group compared to the placebo group (Table 4). 
Although fasting basal insulin and HOMA-I were similar at 
baseline between the two groups, 8-month follow-up fasting 
basal insulin and HOMA-I were significantly lower in the 
pioglitazone group, compared to the placebo group (Table 4). 
Moreover, adiponectin levels increased significantly only in 
the pioglitazone group. Fasting glucose, RBP-4, and hsCRP 
concentrations showed no significant difference between the 
two groups during the 8-month follow-up period. Moreover, 
Table 3. Atherosclerosis progression during the follow-up period
Pioglitazone (n=19) Placebo (n=18)
Baseline 8 months Baseline 8 months
Vessel volume (mm
3/mm) 13.02±6.93 12.85±6.51 16.93±8.57 17.43±8.70
Change -0.17±1.2600 0.50±2.53
Lumen volume (mm
3/mm) 07.84±6.09 0.7.61±5.20† 10.32±5.99 09.66±5.41
Change -0.23±1.4400 -0.66±2.510
Atheroma volume (mm
3/mm) 05.18±2.69 05.24±2.89 06.61±4.66 007.77±4.47*
Change 0.06±0.73†0 1.16±1.41
Percentage change (%) 2.91±17.99† 36.96±52.45
*p<0.05 vs. baseline, †p<0.05 vs. placebo
Fig. 1. A: changes in neointima volume and atheroma volume during the 8 month follow-up period. B: changes in atheroma volume are further 
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changes from baseline in lipid profiles showed no significant 
difference between the two groups (Table 4). Changes from 
baseline in IL-6 (r=0.354, p=0.032) and TNF-alpha (r=0.412, 
p=0.043) levels demonstrated positive correlations with neo-
intima volume in the pioglitazone group. The rates of MACE 
during the follow-up period were similar between the 2 groups.
Discussion
Retinopathy, neuropathy and nephropathy are the major mi-
crovascular complications in diabetes, and many studies re-
vealed that intensive glycemic control reduced these micro-
vascular complications.
10) Oral glucose lowering medications, 
such as glimepiride and metformin, were not effective in low-
ering the incidence of macrovascular complications present 
as cardiovascular disease in type 2 diabetic patients.
11) PPAR-γ 
agonists, such as pioglitazone and rosiglitazone are known 
insulin sensitizers. They demonstrate anti-inflammatory and 
anti-proliferative effects in addition to glycemic control.
5) 
Although the exact mechanisms on how TZDs improve in-
sulin sensitivity are not completely revealed, TZDs may im-
prove insulin sensitivity by stimulating adipose differentiation 
and regulating genes that encode GLUT4.
12)13) This insulin sen-
sitizing effect is considered to be good influence on cardio-
vascular diseases, because insulin resistance is considered non-
traditional risk factors for cardiovascular disease in diabetic 
patients.
14) Previous data suggested that TZDs could have an-
ti-atherogenic effects, and pioglitazone slowed atherosclero-
sis progression in the carotid artery.
8) The PERISCOPE study 
revealed the effects of pioglitazone on lowering the progres-
sion rate of coronary atheroma, compared to glimepiride,
9) and 
the effect of slowing atherosclerosis progression was not as-
sociated with the glucose lowering effect of pioglitazone.
9) The 
relationship between atherosclerosis progression and im-
provement in insulin resistance was not clearly revealed in 
our study, probably due to the small study population. It must 
be emphasized that the majority of patients in the PERISCO-
PE study were Caucasians, who showed a high BMI (>32 kg/
m
2 in both glimepiride and pioglitazone groups) and high fast-
ing serum insulin levels (>21 μIU/mL in both glimepiride and 
pioglitazone groups) at the beginning of the study. Most pa-
tients in the PERISCOPE study had type 2 diabetes with high 
insulin resistance, which constituted the major subgroup of 
type 2 diabetes in Western countries. However, Korean type 
2 diabetic patients are known to differ from that of Western 
countries: Korean type 2 diabetes have relatively lower BMI 
with low fasting serum insulin levels.
15-17) Most patients in our 
study had insulin secretory defects.
15-17) Our study population 
also showed relatively low BMI (average 25.5 kg/m
2) and low 
fasting serum insulin level (average 11.4 μIU/mL), compared 
to that of the PERISCOPE study. One might ask whether pi-
oglitazone could have a similar effect of reducing the rate of 
atherosclerosis progression in Koreans, as demonstrated in a 
previous trial.
9) 
We also compared changes in the levels of RBP-4 in addi-
tion to HOMA index as markers of the insulin sensitivity, to 
determine in detailed the relationship between reduction in 
atherosclerosis progression and reduction in insulin resistance. 
However, no relationship between atherosclerosis progres-
sion and insulin resistance was found. Furthermore, we could 
not determine any relationship between RBP-4 concentra-
tions with atherosclerosis progression and neointima forma-
tion, and there was no correlation between atherosclerosis pro-
gression and changes in HOMA-index levels. IL-6 and TNF-α 
Table 4. Changes in the levels of inflammatory, insulin resistance markers and lipid profile during the follow-up period
Pioglitazone (n=19) Placebo (n=18)
Baseline 8 months Baseline 8 months
IL-6 (pg/mL) 001.20±0.47 000.69±0.24*
† 001.49±0.32 001.14±0.26*
TNF-α (pg/mL) 012.24±4.77 009.59±2.38*
† 011.61±3.11 012.47±3.33
hs-CRP (mg/L) 001.34±0.95 001.05±0.97 001.60±1.82 000.70±0.46*
Adiponectin (μg/mL) 0005.7±5.2 0007.7±3.9*
† 0006.0±2.7 0006.4±3.3
Fasting insulin (μIU/mL) 011.04±2.45 008.54±1.21*
† 011.84±3.05 009.73±1.55*
Fasting glucose (mg/dL) 180.43±75.30 138.64±40.51* 161.71±37.28 158.43±44.95
HOMA index 004.77±1.76 002.94±0.91*
† 004.74±1.59 003.80±1.21
RBP-4 (μg/mL) 051.81±15.65 053.53±16.31 057.41±22.71 062.92±20.39
Hemoglobin A1c (%) 007.63±1.40 006.99±0.91 007.73±2.19 007.73±1.35
Total cholesterol (mg/dL) 163.93±37.67 144.50±35.62* 158.86±36.08 135.14±19.98*
Triglycerides (mg/dL) 168.64±93.79 153.67±78.99 130.21±73.36 147.50±73.63
HDL-C (mg/dL) 041.71±8.27 039.83±10.34 045.79±13.50 041.93±7.59
LDL-C (mg/dL) 109.79±29.86 079.87±23.23* 105.43±29.70 074.50±17.02*
*p<0.05 vs. baseline, †p<0.05 vs. placebo. hs-CRP: high-sensitivity C-reactive protein, HDL-C: high density lipoprotein-cholesterol, IL-6: inter-
leukin-6, LDL-C: low density lipoprotein-cholesterol, TNF-α: tumor necrosis factor-alphaSung Hye You, et al.   631
levels at 8-month follow-up decreased significantly in the 
pioglitazone group, compared to the placebo group. IL-6 and 
TNF-α are representative of adipokine. Many studies showed 
the effects of pioglitazone on reducing inflammatory mark-
ers, such as TNF-α levels,
18) and some animal studies showed 
neutralization of TNF-α caused significant increase in insu-
lin sensitivity by increasing peripheral uptake of glucose.
19) 
We also showed that pioglitazone has IL-6 and TNF-α low-
ering effects, thereby reducing atherosclerosis progression. 
No correlation between atherosclerosis progression and 
neointima volume was found in our study. Several hypothe-
ses could be put forward about this finding. First, a false ne-
gative result may be due to the small population size. Second, 
there could be a different mechanism between atherosclerosis 
progression and neointima proliferation. Third, zotarolimus 
compared may have stronger effects on neointima prolifera-
tion, and zotarolimus had a small effect on atherosclerosis 
progression 20 mm proximal and distal to the stent. One ani-
mal study showed TZDs decreased neointima proliferation 
by decreasing smooth muscle cell growth and inflammation.
20) 
Our study did not address the mechanisms of pioglitazone in 
reducing atherosclerosis progression and neointima prolif-
eration. The PROactive study showed MACEs reduction in 
the pioglitazone groups, compared to the placebo group.
21) 
Decrease in atherosclerosis progression and neointima pro-
liferation in the pioglitazone group did not translate into ben-
efits in MACEs at the 8-month follow-up in our study, and a 
long-term study with larger study population is warranted. 
We did not find any complications with pioglitazone therapy, 
such as edema, weight gain and bone fracture during the 8- 
month follow-up period. 
In conclusion, pioglitazone treatment, when compared with 
placebo, was associated with significant reduction in athero-
sclerosis progression and neointima proliferation in patients 
with type 2 diabetic following ZES implantation, and these 
findings were associated with the anti-inflammatory effects 
of pioglitazone.
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